Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. A 6-year, case-control study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN45507228

Enrollment

400

Registered

2007-02-26

Start date

2000-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral psoriatic arthritis Musculoskeletal Diseases arthritis

Interventions

Traditional DMARDs vs anti-TNF agents

Eligibility

Inclusion criteria

Inclusion criteria: Case patients: consecutive new outpatients with peripheral psoriatic arthritis requiring second-line drugs Controls: consecutive new outpatients with rheumatoid arthritis

Exclusion criteria

Exclusion criteria: Patients with inflammatory spinal pain at presentation or during the disease course, or meeting the modified New York criteria for ankylosing spondylitis, and those with contraindications to the use of traditional DMARDs and anti-TNFa drugs.

Design outcomes

Primary

Measure	Time frame
Modified American College of Rheumatology (ACR) criteria for clinical remission	—

Secondary

Measure	Time frame
Duration of clinical remission during treatment and after therapy interruption, to evaluate the ACR 20, 50, 70 response rates at the end of follow up, and to evaluate the correlation between initial clinical and laboratory variables and the frequency of remissions.	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026